10.70 USD
▼-0.46-4.12%
盘后 10.95 +2.34%
2026-09-15
市值
$295.51M
市盈率
—
EPS
-0.20
股息率
—
52 周区间
10.47 – 17.80
成交量
20.28K
Beta
0.12
目标价
—
52W 低 10.4752W 高 17.80
价格走势
公司简介
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III cl...